Cicletanine reverses vasoconstriction induced by the endogenous sodium pump ligand, marinobufagenin, via a protein kinase C dependent mechanism

Journal of Hypertension

Volumn 18, Issue 2, 2000, Pages 209-215

  Bagrov, Alexei Y ^a,b   Dmitrieva, Renata I ^b   Dorofeeva, Natalia A ^b   Fedorova, Olga V ^a   Lopatin, Denis A ^b   Lakatta, Edward G ^a   Droy Lefaix, Marie Therese ^c  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b SECHENOV INSTITUTE OF EVOLUTIONARY PHYSIOLOGY AND BIOCHEMISTRY   (Russian Federation)

^c IPSEN   (France)

Author keywords

Cicletanine; Hypertension; Marinobufagenin; Na K ATPase; Protein kinase C

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) INHIBITOR; CARDIAC GLYCOSIDE; CICLETANINE; CYCLIC GMP PHOSPHODIESTERASE; ENDOTHELIN 1; MARINOBUFAGENIN; PHORBOL DIACETATE; PROTEIN KINASE C; STEROID; UNCLASSIFIED DRUG;

ARTICLE; BLOOD LEVEL; BLOOD VESSEL TONE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; HYPERTENSION; MESENTERIC ARTERY; PRIORITY JOURNAL; SARCOLEMMA; VASOCONSTRICTION; VASODILATATION;

EID: 0034000644     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200018020-00012     Document Type: Article

References (37)

1. 1 Auguet M, Delaflotte S, Braquet P. Interaction entre le facteur natriuretique atrial et le cicletanine vis-ȧ-vis de la contraction induite par l'endotheline et la phenylephrine sur l'aorte isolee de rat. Arch Mal Coeur Vas 1989; 82:59-62.
2. 2 Alvarez-Guerra M, Alda O, Morin E, Allard M, Garay RP. Reduction of the cicletanine reactivity to angiotensin II in rats. J Cardiovasc Pharmacol 1996; 28:564-570.
3. 3 Garay RP, Rosati C, Fanous K. Evidence for (+)-cicletanine sulfate as an active natriuretic metabolite of cicletanine in the rat. EUT J Pharmacol 1995; 274:125-137.
4. 4 Schoeffter P, Ghysel-Burton J, Cabanie M, Godfraind T. Competitive and stereoselective histamine H1 antagonistic effect of cicletanide in guinea pig isolated ileum. Eur J Pharmacol 1987; 136:235-237.
5. 5 Dorian B, Larrue J, Defeudis FV, Salari H, Borgeat P, Braquet P. Activation of prostacyclin synthesis in cultured aortic smooth muscle cells by diureticantihypertensive drugs. Biochem Pharmacol 1984; 33:2265-2269.
6. m cyclic GMP phosphodiesterases and Ca-regulated protein kinases and relationship to vasorelaxation by cicletanine. J Pharmacol Exp Ther 1991; 257:382-389.
7. 7 Jin HK, Yang RH, Esunge P, Chen YF, Oparil S. Antihypertensive effect of cicletanine is exaggerated in NaCl-sensitive hypertension. Am J Med Sci 1991; 301:383-389.
8. 8 Uehara Y, Numabe A, Hirawa N, Kawabata Y, Iwai J, Ono H, et al. Antihypertensive effects of cicletanine and renal protection in Dahl saltsensitive rats. J Hypertens 1991; 9:719-828.
9. 9 Uehara Y, Hirawa N, Kawabata Y, Akie Y, Ichikawa A, Funahashi N, et al. Lipid metabolism and renal protection by chronic cicletanine treatment in Dahl salt-sensitive rats with salt induced hypertension. Blood Pressure 1997; 6:180-187.
10. 10 Ludens JH, Clark MA, Du Charme DW, Lutzke BS, Mandel F. Mathews WR, et al. Purification of an endogenous digitalis-like factor from human plasma for structural analysis. Hypertension 1991; 17:923-929.
11. 11 Bagrov AY, Fedorova OV, Austin JL, Dmitrieva RI, Anderson DE. Endogenous marinobufagenin-like immunoreactive factor and Na,K-ATPase inhibition during voluntary hypoventilation. Hypertension 1995; 26:781 -788.
12. 12 Bagrov AY, Fedorova OV, Dmitrieva RI, Howald WN, Hunter AP, Kuznetsova EA, et al. Bufodienolide nature of endogenous inhibitor of Na/K ATPase in the urine from patients with acute myocardial infarction. Hypertension 1998; 31:1097-1103.
13. 13 Fedorova OV, Bagrov AY. Inhibition of Na/K ATPase from rat aorta by two endogenous Na/K pump inhibitors, ouabain and marinobufagenin. Evidence of interaction with different a-subunit isoforms. Am J Hypertens 1997; 10:929-935.
14. 14 Nguyen A-T, Hayward-Lester A, Sabatini S, Doris PA. Renal Na,K ATPase in SHR: studies of activity and gene expression. Ctin Exp Hypertens 1998; 11:641-656.
15. 15 Fedorova OV, Anderson DE, Bagrov AY. Endogenous digitalis-like factors and Na,K-ATPase inhibition in ACTH hypertension in rats. Am J Hypertens 1998; 11:796-802.
16. 16 Fedorova OV, Lakatta EG, Bagrov AY. Endogenous ligands of the Na,K pump in NaCl induced hypertension [Abstract]. Circulation 1998; 98:1-377.
17. 17 Lopatin DA, Ailamazian EK, Dmitrieva RI, Shpen VM, Fedorova OV, Doris PA, ef al. Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia. J Hypertens 1999; 17:1179-1187.
18. 18 Gonick HC, Ding Y, Vaziri ND, Bagrov AY, Fedorova OV. Simultaneous measurement of marinobufagenin, ouabain and hypertension-associated protein in various disease state. Clin Exp Hypertens 1998; 20:617-627.
19. 19 Bagrov AY, Fedorova OV. Effects of two putative endogenous digitalis-like factors, marinobufagenin and ouabain, on the Na/K pump in human mesenteric arteries. J Hypertens 1998; 16:1953-1958.
20. 20 Bagrov AY, Roukoyatkina NI, Dmitrieva RI, Pinaev AG, Fedorova OV. Effects of two endogenous digitalis-like factors, ouabain and marinobufagenin in isolated rat aorta. Eur J Pharmacol 1995 ; 274:151 -158.
21. m cyclic GMP phosphodiesterases and potentiation of gunylate cyclase activators by cicletanine. J Cardiovasc Pharmacol 1990; 16:501 -505.
22. 22 Bagrov AY, Droy-Lefaix M-T, Dmitrieva RI. Vasorelaxant effects of cicletanine and its (+)-and (-)-enantiomers in isolated human pulmonary arteries. Am J Hypertens 1998; 11:1386-1389.
23. 23 Gupta S, Ruderman NB, Cragoe EJ, Sussman I. Endothelin stimulates Na,K-ATPase activity by a protein kinase C-dependent pathway in rabbit aorta. Am J Physiol 1991 ; 261 :H38-H45.
24. 24 Gorlach C, Benyo Z, Wahl M. Endothelin-1 -induced contraction in cerebral vessels mediated by phospholipase C/protein kinase C cascade. Kidney Int 1998; 54 (suppl 67): S224-S225.
25. 25 Oriji GK, Keiser HR. Action of protein kinase C in endothelin-induced contractions in rat aortic rings. Am J Physiol 1996; 271 :C398-C404.
26. 26 Steffan M, Russell JA. Signal transduction in endothelin-induced contraction of rabbit pulmonary vein. Pulm Pharmacol 1990; 3:1 -7.
27. 27 Murphy M, McGinty A, Godson C. Protein kinases C: potential targets for intervention in diabetic nephropathy. Curr Opin Nephrot Hypertens 1998; 7:563-570.
28. 28 Brock TA, Lewis LJ, Smith JB. Angiotensin increases Na entry and Na/K pump activity in cultures of smooth muscle from rat aorta. Proc Natl Acad Sci USA 1982; 79:1438-1442.
29. 29 Rappoport RM, Schwartz K, Murad F. Effect of sodium-potassium pump inhibitors and membrane depolarizing agents on sodium nitroprusside-induced relaxation and cyclic guanosine monophosphate accumulation in rat aorta. Circ Res 1985; 114:1731-1737.
30. 30 Perez-Vizcaino F, Cogolludo A, Tamargo J. Modulation of arterial Na-K-ATPase-induced reduction and relaxation by norpepinephrine, ET-1, and PMA. Am J Physiol 1999; 276:H651 -H657.
31. 18 occurs in intact cells but does not result in direct inhibition of ATP hydrolysis. J Biol Chem 1997; 272:17726-17733.
32. 32 Pedersen PA, Rasmussen JH, Jorgensen PL. Consequences of mutations to the phosphorylation site of the a-1 subunit of Na,K-ATPase for ATP binding and E1 -E2 conformational equilibrium. Biochemistry 1996; 35:16085-16093
33. 33 Kometiani P, Li J, Gnudi L, Kahn BB, Askari A, Xie Z. Multiple signal transduction pathways fink Na/K-ATPase to growth-related genes in cardiac myocytes. J Biol Chem 1998; 273:15249-15267.
34. 34 Numazawa S, Honma Y, Yamamoto T, Yoshida T, Kuroiwa Y. A cardiotonic steroid bufalin-like factor in human plasma induces leukemia cell differentiation. Leuk Res 1995; 19:945-953.
35. 35 Watabe M, Masuda Y, Nakajo S, Yoshida T, Kuroiwa Y, Nakaya K. The cooperative interaction of two different signaling pathways in response to bufalin induces apoptosis in human leukemia U937 cells. J Biol Chem 1996; 271:14067-14072.
36. 36 Bukoski RD, Bo J, Xue H, Brian K. Antiproliferative and endothelium-dependent vasoconstrictor properties of 1,2-dihydro-3-p-chlorphenyl-7-hydroxy-6-methyl-furo-(3,4c) pyridine hydrochloride (cicletanine). J Pharmacol Exp Ther 1993; 265:30-35.
37. 37 Chabrier PE, Esanu A, Braquet P. Vascular remodeling and antihypertensive therapy; the example of cicletanine. J Cardiovasc Pharmacol 1993; 21 (suppl 1):S50-S53.